-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
Recently, Nature Communications, a subsidiary of Nature, published online the clinical Phase 2 trial data of Junshengtai's original innovative drug HTD1801 for non-alcoholic steatohepatitis with type 2 diabetes (NASH + T2DM)
Screenshot source: reference [1]
Public information shows that HTD1801 is an oral multifunctional small molecule drug independently developed by Junshengtai
In this article, the authors report a prospective, randomized, double-blind, placebo-controlled trial in 100 subjects with NASH + T2DM to test two doses of HTD1801 (500mg and 1000mg) Efficacy and safety compared with placebo
The results showed that the 18-week clinical trial reached the pre-set primary clinical endpoint
According to the authors, this improvement in liver fat content is related to improved blood sugar control, significant improvement in liver inflammation and damage, as well as lower serum levels of liver-related enzymes, significant weight loss, and a moderate reduction in serum lipid levels
In terms of safety and tolerability, studies have shown that HTD1801 treatment is generally well tolerated
NASH is a serious form of non-alcoholic fatty liver disease (NAFLD).
Reference materials:
[1]Harrison, SA, Gunn, N.
[2] "Nature" sub-Journal published HTD1801 Phase II clinical trial data.
(The original text has been deleted)
